Full-Time

HEOR Director

Confirmed live in the last 24 hours

Alector

Alector

201-500 employees

Develops therapies for neurodegenerative diseases

Biotechnology
Healthcare

Compensation Overview

$261k - $282kAnnually

Senior

Remote in USA

Category
Public Health
Biology & Biotech
Requirements
  • Advanced degree (PhD, PharmD, MD, or Master’s) in Health Economics, Epidemiology, Public Health, or a related field.
  • Minimum of 5 years of experience in HEOR, preferably within the pharmaceutical or biotechnology industry.
  • Proven track record of developing and implementing HEOR strategies that support product launches and market access.
  • Strong understanding of payer perspectives and the healthcare reimbursement landscape.
  • Excellent communication and presentation skills.
  • Experience working in neurology and rare diseases is highly desirable.
  • Launch experience in neurology and rare disease.
Responsibilities
  • Build the HEOR strategy and plan for each program including design and execution of HEOR studies, including, literature reviews, burden of illness analyses, budget impact models, cost-effectiveness models, patient-reported outcomes, and real-world evidence.
  • Effective presentation of research findings to internal and external stakeholders.
  • Work collaboratively with alliance partners to ensure the success of our programs.
  • Collaborate cross-functionally with medical affairs, marketing/commercial, regulatory, market access, and clinical teams to ensure evidence and outcomes data are integrated into clinical studies, commercialization plans and payer engagements.
  • Develop and communicate HEOR data of varying levels of complexity to formulary and healthcare policy decision-makers in compliance with company policies.
  • Develop the global value dossier, AMCP dossier, and value messages for payer interactions.
  • Stay up to date with advancements in health economics methodologies and best practices.
  • Identify and work with regional and national HEOR & RWE experts and organizations.
  • Closely monitor national and regional changes in healthcare policy and the payer environment and communicate the impact on the company.

Alector develops therapies aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's. The company focuses on research and development of new drug candidates by utilizing knowledge from immunology, neurology, and human genetics. Their approach involves conducting early-stage clinical trials to gather specific data about diseases, which helps improve the chances of success for their treatments. Alector differentiates itself from competitors by emphasizing the body's natural healing processes in their drug development. The company's goal is to create effective treatments for conditions that currently have limited options, while also attracting funding and partnerships through their research findings.

Company Stage

IPO

Total Funding

$189.2M

Headquarters

San Francisco, California

Founded

2013

Growth & Insights
Headcount

6 month growth

0%

1 year growth

4%

2 year growth

-8%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in neuroimmunology boosts investment opportunities for Alector.
  • AI and machine learning accelerate Alector's R&D efficiency in drug discovery.
  • FDA's fast-tracking of neurodegenerative treatments could expedite Alector's clinical trials.

What critics are saying

  • Failure in clinical trials like AL002 can decrease investor confidence.
  • Reliance on external financing increases financial risk if therapies don't succeed.
  • Competition from major companies like GSK could overshadow Alector's market presence.

What makes Alector unique

  • Alector combines antibody technology with neuroimmunology for novel Alzheimer's treatments.
  • Strategic alliance with Adimab enhances Alector's antibody discovery and optimization capabilities.
  • Focus on human genetics aligns with personalized medicine trends in drug development.

Help us improve and share your feedback! Did you find this helpful?